Overview

EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
Phase:
Phase 2
Details
Lead Sponsor:
Endo Pharmaceuticals